Ellis, I.O., Dowsett, M., Bartlett, J., Walker, R., Cooke, T., Gullick, W., Gusterson, B., Mallon, E., and Lee, P.B. (2000) Recommendations for HER2 testing in the UK. Journal of Clinical Pathology, 53(12), pp. 890-892.
Publisher's URL: http://jcp.bmjjournals.com/cgi/content/full/53/12/890
Determining the HER2 status of breast carcinomas is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin(R)), which has recently been licensed for the treatment of metastatic disease. This necessitates a test based on archival material. The preferred analyses are immunohistochemistry with fluorescent in situ hybridisation (FISH) as a follow up test for ambiguous results. Guidelines have been developed for standardised, well controlled procedures for the provision of reliable results. A group of three reference laboratories has been established to provide advice, quality assurance, and materials, where needed.
|Glasgow Author(s) Enlighten ID:||Gusterson, Professor Barry and Cooke, Prof Timothy|
|Authors:||Ellis, I.O., Dowsett, M., Bartlett, J., Walker, R., Cooke, T., Gullick, W., Gusterson, B., Mallon, E., and Lee, P.B.|
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)|
R Medicine > RB Pathology
|College/School:||College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences|
|Journal Name:||Journal of Clinical Pathology|
|Publisher:||BMJ Publishing Group Ltd.|
|Copyright Holders:||Copyright © 2001 by the Journal of Clinical Pathology and Association of Clinical Pathologists|
|First Published:||First published in the Journal of Clinical Pathology 53(12):890-892|
|Publisher Policy:||Reproduced in accordance with the copyright policy of the publisher|
Enlighten Editors: Update this record